ABL1 and acute lymphoblastic leukemia: Though the efficacy of single‐agent tyrosine kinase inhibitor (TKI) therapy for Ph‐positive ALL is poor, the combination of ABL1 inhibitors with conventional chemotherapy largely improves the response and survival and now is standard of care for Ph‐positive ALL.56